摘要
目的:对重组活化人凝血因子Ⅶ进行药物经济学考察。方法:采用文献回顾方法,对血友病药物费用及影响因素进行探讨。结果:重组活化人凝血因子Ⅶ治疗血友病止血时间短。相对于激活凝血酶原复合物,重组活化人凝血因子Ⅶ更具成本-效果优势,其治疗费用的最主要影响因素并不一定是价格。结论:重组活化人凝血因子Ⅶ的价格不应成为限制其临床应用的依据。
OBJECTIVE： To conduct pharmacoeconomic investigation of recombinant activated factor Ⅶ. METHODS： By literature review, drug cost and influencing factor of haemophilia were investigated. RESULTS： The recombinant activated factor had quick effectiveness of stopping hemorrhage and advantage of cost-effectiveness as compared with activated prothrombin compound. Price may not be main influencing factor for the treatment expenditure. CONCLUSION： Price should not be used as basis for limiting the clinical application of recombinant activated factor Ⅶ.
出处
《中国药房》
CAS
CSCD
北大核心
2010年第46期4321-4323,共3页
China Pharmacy
